AB AB Science SA

AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection

AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection

PRESS RELEASE



AB SCIENCE RECEIVES CHINESE PATENT PROTECTING MASITINIB IN THE TREATMENT OF COVID-19 UNTIL 2041, ADDING ONE MORE INDICATION WITH LONG TERM INTELLECTUAL PROPERTY PROTECTION

Paris, May 19, 2025, 8am CET

AB Science SA (Euronext - FR0010557264 - AB) today announced that the Chinese Patent Office has issued a patent relating to methods of treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing COVID-19 (i.e. a medical use patent) with its lead compound masitinib. This new Chinese patent provides intellectual property protection for masitinib in this indication until April 2041.

As part of a collaborative research agreement with the University of Chicago, AB Science signed an exclusive licensing agreement to conduct research for the prevention and treatment of COVID-19 with masitinib and other AB Science proprietary drugs [1]. In case of commercialization in viral disease, AB Science will benefit from an exclusive, royalty-bearing license on any discoveries made with AB Science products (1% of net sales on first registered product and 0.3% of net sales on further registered product to be paid to the University of Chicago).

The patent is based in part on preclinical data that has been published in the world-renowned journal Science, and which identified masitinib as a broad antiviral agent capable of treating SARS-CoV-2 (the virus that causes COVID-19), including demonstration of in vivo activity in mice, with efficacy maintained, in vitro, against SARS-CoV-2 variants of concern [2].

AB Science also recently communicated the positive results of its phase 2 study evaluating masitinib in COVID-19. At that time, Professor Olivier Hermine, MD, President of the Scientific Committee of AB Science and member of the Académie des Sciences in France commented, “This result confirms the anti-inflammatory activity of masitinib, by controlling activated macrophages and mast cells involved in COVID. In addition, several publications highlighted the capacity of masitinib to act as an indirect broad antiviral agent against COVID. With this result, masitinib can be considered a drug of choice to be evaluated in the context of a future pandemic” [3].

Reference

[1] AB Science press release, April 6, 2021. -science.com/signing-of-an-exclusive-licensing-agreement-with-the-university-of-chicago-to-conduct-research-for-the-prevention-and-treatment-of-covid-19/

[2] Drayman N, DeMarco JK, Jones KA, et al. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science. 2021;373(6557):931-936. doi:10.1126/science.abg5827

[3] AB Science press release, July 8, 2024. -science.com/positive-results-of-the-phase-2-study-evaluating-masitinib-in-covid-19/

About AB Science

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment.

AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science’s website: .

Forward-looking Statements - AB Science

This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.

These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.

For additional information, please contact:

AB Science

Financial Communication & Media Relations

Attachment



EN
19/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AB Science SA

 PRESS RELEASE

AB Science provides an update on the renegotiation of loan repayment t...

AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE RENEGOTIATION OF LOAN REPAYMENT TERMS WITH ITS FINANCIAL CREDITORS AGREEMENT IN PRINCIPLE HAS BEEN REACHED ON A TWO-YEAR DEFERRAL OF REPAYMENT OF STATE-GUARANTEED LOANS SAVINGS OVER THE PERIOD WILL BE INVESTED IN R&DTHIS AGREEMENT IS CONDITIONAL ON THE REPAYMENT DATE OF THE EIB COVID LOAN BEING POSTPONED, NEGOTIATIONS ON WHICH ARE CURRENTLY UNDERWAY. Paris, June 30, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today anno...

 PRESS RELEASE

AB Science fait un point sur la renégociation des modalités de rembour...

AB Science fait un point sur la renégociation des modalités de remboursement de ses emprunts avec ses créanciers financiers COMMUNIQUE DE PRESSE AB SCIENCE FAIT UN POINT SUR LA RENEGOCIATION DES MODALITES DE REMBOURSEMENT DE SES EMPRUNTS AVEC SES CREANCIERS FINANCIERS UN ACCORD DE PRINCIPE A ETE OBTENU SUR UN DECALAGE DE DEUX ANS DU REMBOURSEMENT DES PRETS GARANTIS PAR L’ETAT L’ECONOMIE SUR LA PERIODE SERA INVESTIE EN R&DCET ACCORD EST CONDITIONNEE PAR LE DECALAGE DE LA DATE DE REMBOURSEMENT DU PRET BEI COVID DONT LA NEGOCIATION EST EN COURS Paris, 30 juin 2025, 8h AB Science SA (Eurone...

 PRESS RELEASE

AB Science - New peer-reviewed data provide strong evidence supporting...

AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease PRESS RELEASE NEW PEER-REVIEWED DATA PROVIDE STRONG EVIDENCE SUPPORTING MASITINIB’S POTENTIAL FOR THE TREATMENT OF ALZHEIMER’S DISEASE THROUGH A DUAL MECHANISM OF COGNITIVE ENHANCEMENT AND NEUROPROTECTION THIS PUBLICATION CORROBORATES NEW ANALYSIS FROM THE CLINICAL PHASE 2B/3 STUDY SHOWING COGNITIVE IMPROVEMENT UNDER MASITINIB TREATMENT PHASE 3 CLINICAL STUDY WITH MASITINIB AS A DISEASE-MODIFYING THERAPY FOR ALZHEIMER’S DISEASE HAS BEEN AUTHORIZED BY THE FD...

 PRESS RELEASE

AB Science - De nouvelles données évaluées par des pairs apportent des...

AB Science - De nouvelles données évaluées par des pairs apportent des preuves solides du potentiel du masitinib dans le traitement de la maladie d’Alzheimer COMMUNIQUE DE PRESSE DE NOUVELLES DONNÉES ÉVALUÉES PAR DES PAIRS APPORTENT DES PREUVES SOLIDES DU POTENTIEL DU MASITINIB DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER GRÂCE À UN DOUBLE MÉCANISME D'AMÉLIORATION COGNITIVE ET DE NEUROPROTECTION CETTE PUBLICATION CONFIRME LES NOUVELLES ANALYSES DE L'ÉTUDE CLINIQUE DE PHASE 2B/3 MONTRANT UNE AMÉLIORATION COGNITIVE AVEC LE MASITINIB L'ÉTUDE CLINIQUE DE PHASE 3 AVEC LE MASITINIB COMME TRAIT...

 PRESS RELEASE

AB Science announces issuance of a Canadian patent protecting the comp...

AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036 PRESS RELEASE AB SCIENCE ANNOUNCES ISSUANCE OF A CANADIAN PATENT PROTECTING THE COMPOSITION OF MATTER OF AB8939, INCLUDING ITS USE IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML), WITH PROTECTION UNTIL 2036 THIS PATENT COMPLETES INTELLECTUAL PROPERTY COVERAGE FOR AB8939 ACROSS ALL KEY GEOGRAPHIC AREAS WHERE IT COULD BE MARKETED, INCLUDING EUROPE, USA, CHINA, JAPAN AND SOUTH KOREA, INDIA, ISRAEL, LATIN A...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch